These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 31727235)

  • 21. Microarray Approach Combined with ddPCR: An Useful Pipeline for the Detection and Quantification of Circulating Tumour dna Mutations.
    Galbiati S; Damin F; Ferraro L; Soriani N; Burgio V; Ronzoni M; Gianni L; Ferrari M; Chiari M
    Cells; 2019 Jul; 8(8):. PubMed ID: 31344983
    [No Abstract]   [Full Text] [Related]  

  • 22. Monitoring of Response and Resistance in Plasma of EGFR-Mutant Lung Cancer Using Droplet Digital PCR.
    Kuang Y; O'Connell A; Sacher AG; Feeney N; Alden RS; Oxnard GR; Paweletz CP
    Methods Mol Biol; 2018; 1768():193-207. PubMed ID: 29717445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review.
    Petit J; Carroll G; Gould T; Pockney P; Dun M; Scott RJ
    J Surg Res; 2019 Apr; 236():184-197. PubMed ID: 30694754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toward liquid biopsies in cancer treatment: application of circulating tumor DNA.
    Barlebo Ahlborn L; Østrup O
    APMIS; 2019 May; 127(5):329-336. PubMed ID: 30784124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating Tumor DNA: A Step into the Future of Cancer Management.
    Fernandes Marques J; Pereira Reis J; Fernandes G; Hespanhol V; Machado JC; Costa JL
    Acta Cytol; 2019; 63(6):456-465. PubMed ID: 30852572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies.
    Gorgannezhad L; Umer M; Islam MN; Nguyen NT; Shiddiky MJA
    Lab Chip; 2018 Apr; 18(8):1174-1196. PubMed ID: 29569666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management.
    Fici P
    Methods Mol Biol; 2019; 1909():47-73. PubMed ID: 30580422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Technical considerations for circulating tumor DNA detection in oncology.
    Franczak C; Filhine-Tresarrieu P; Gilson P; Merlin JL; Au L; Harlé A
    Expert Rev Mol Diagn; 2019 Feb; 19(2):121-135. PubMed ID: 30648442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single Color Multiplexed ddPCR Copy Number Measurements and Single Nucleotide Variant Genotyping.
    Wood-Bouwens CM; Ji HP
    Methods Mol Biol; 2018; 1768():323-333. PubMed ID: 29717451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Introduction and Clinical Application of Cell-Free Tumor DNA.
    Li J; Liu R; Huang C; Chen S; Xu M
    Methods Mol Biol; 2018; 1754():45-65. PubMed ID: 29536437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of incipient tumours by screening of circulating plasma DNA: hype or hope?
    Lenaerts L; Tuveri S; Jatsenko T; Amant F; Vermeesch JR
    Acta Clin Belg; 2020 Feb; 75(1):9-18. PubMed ID: 31578135
    [No Abstract]   [Full Text] [Related]  

  • 32. Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients.
    van Ginkel JH; Huibers MMH; van Es RJJ; de Bree R; Willems SM
    BMC Cancer; 2017 Jun; 17(1):428. PubMed ID: 28629339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
    Cheng F; Su L; Qian C
    Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Developing Ultrasensitive Library-Aliquot-Based Droplet Digital PCR for Detecting T790M in Plasma-Circulating Tumor DNA of Non-small-Cell-Lung-Cancer Patients.
    Yang K; Li J; Zhao J; Ren P; Wang Z; Wei B; Dong B; Sun R; Wang X; Groen HJM; Ma J; Guo Y
    Anal Chem; 2018 Oct; 90(19):11203-11209. PubMed ID: 30156405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review.
    Chen X; Wang L; Lou J
    Med Sci Monit; 2020 Mar; 26():e921040. PubMed ID: 32200389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA.
    Luo H; Wei W; Ye Z; Zheng J; Xu RH
    Trends Mol Med; 2021 May; 27(5):482-500. PubMed ID: 33500194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How liquid biopsies can change clinical practice in oncology.
    Siravegna G; Mussolin B; Venesio T; Marsoni S; Seoane J; Dive C; Papadopoulos N; Kopetz S; Corcoran RB; Siu LL; Bardelli A
    Ann Oncol; 2019 Oct; 30(10):1580-1590. PubMed ID: 31373349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
    Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
    Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liquid biopsy of circulating tumor DNA and biosensor applications.
    Li X; Ye M; Zhang W; Tan D; Jaffrezic-Renault N; Yang X; Guo Z
    Biosens Bioelectron; 2019 Feb; 126():596-607. PubMed ID: 30502682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating Tumor DNA (ctDNA) and Its Role in Gynecologic Malignancies.
    Pomerantz T; Brooks R
    Curr Treat Options Oncol; 2024 Apr; 25(4):510-522. PubMed ID: 38472567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.